View ValuationARCpoint 将来の成長Future 基準チェック /06現在、 ARCpointの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Healthcare 収益成長52.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • 3hARCpoint Inc. Announces CEO ChangesARCpoint Inc. announced that its Board of Directors had appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. Mr. Kendall’s appointment remains subject to acceptance by the TSX Venture Exchange, including acceptance of the Exchange’s required Personal Information Form and completion of customary Exchange review and verification procedures. In connection with Mr. Kendall’s appointment, John Constantine has stepped down as Chief Executive Officer of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. Peter Kendall has more than twenty years of healthcare commercialization experience. His prior roles include President and Chief Commercialization Officer of AI/ML Innovations Inc., Chief Executive Officer of Yurek Pharmacy Group, and National Director at Medisys Health Group, subsequently acquired by TELUS Health. Mr. Kendall’s initial engagement is for a term of 90 days. During this period, Mr. Kendall will work with the Board and management to assess the Company's business model, MAPL technology platform, commercial relationships, assets and strategic direction, and to provide recommendations to the Board on the best commercial and financial path forward for the Company and its stakeholders.お知らせ • 22hArcpoint Inc. Announces Step Down of John Constantine as PresidentARCpoint Inc. announced that John Constantine has stepped down as President of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. The Company’s Board members remain Zelong “Roger” He, David Keys, John Constantine and Adam Ho.Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Roger He was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 30Arcpoint Inc. Announces Felix Mirando Resignation of Board MemberARCpoint Inc. reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective April 28, 2026.Reported Earnings • Mar 05Full year 2025 earnings released: US$0.017 loss per share (vs US$0.013 profit in FY 2024)Full year 2025 results: US$0.017 loss per share (down from US$0.013 profit in FY 2024). Revenue: US$605.7k (down 89% from FY 2024). Net loss: US$2.12m (down 256% from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.3m free cash flow). Share price has been highly volatile over the past 3 months (39% average weekly change). Negative equity (-US$7.5m). Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (CA$1.28m market cap, or US$918.6k). Minor Risk Revenue is less than US$5m (US$1.5m revenue).Reported Earnings • Nov 30Third quarter 2025 earnings released: US$0.004 loss per share (vs US$0.051 profit in 3Q 2024)Third quarter 2025 results: US$0.004 loss per share (down from US$0.051 profit in 3Q 2024). Revenue: US$113.7k (down 91% from 3Q 2024). Net loss: US$507.2k (down 110% from profit in 3Q 2024).Reported Earnings • Aug 27Second quarter 2025 earnings released: US$0.006 loss per share (vs US$0.015 loss in 2Q 2024)Second quarter 2025 results: US$0.006 loss per share (improved from US$0.015 loss in 2Q 2024). Net loss: US$704.2k (loss narrowed 50% from 2Q 2024).お知らせ • Jul 02ARCpoint Inc., Annual General Meeting, Aug 25, 2025ARCpoint Inc., Annual General Meeting, Aug 25, 2025.Reported Earnings • May 28First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: US$177.4k (down 89% from 1Q 2024). Net loss: US$633.5k (loss narrowed 57% from 1Q 2024).New Risk • May 08New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Negative equity (-US$6.6m). Market cap is less than US$10m (CA$11.6m market cap, or US$8.37m). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (26% increase in shares outstanding).お知らせ • Mar 09ARCpoint Inc. announced that it has received CAD 0.8 million in fundingOn March 7, 2025, ARCpoint Inc., closed the transaction. As a part of the transaction, the company paid CAD 36,057.60 as cash commission, issued 428,400 finder’s shares, 536,400 finder’s warrants. The transaction included participation from Felix Mirando and Adam Ho, purchased or acquired direction or control over a total of 764,199 units as part of the offering.お知らせ • Jan 31ARCpoint Inc. announced that it expects to receive CAD 0.8 million in fundingARCpoint Inc. announced a non-brokered private placement to issue 10,000,000 units at issue price of CAD 0.08 per unit for gross proceeds of CAD 800,000 on January 31, 2025. Each Unit will be comprised of one Class A Subordinate Voting Share of the Company and one warrant to purchase an additional Share at CAD 0.12 for 24 months from closing. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Subject to compliance with applicable securities laws and the approval of the TSX Venture Exchange, finders’ fees may be payable to eligible arm’s length persons with respect to certain subscriptions accepted by the Company.New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (50% average weekly change). Negative equity (-US$6.1m). Earnings have declined by 65% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (CA$9.43m market cap, or US$6.58m).お知らせ • Dec 31An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million.An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million on December 30, 2024. A cash consideration of $0.48 million will be paid by the buyer.Reported Earnings • Nov 29Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.016 loss in 3Q 2023)Third quarter 2024 results: EPS: US$0.051 (up from US$0.016 loss in 3Q 2023). Revenue: US$1.22m (down 24% from 3Q 2023). Net income: US$5.19m (up US$6.64m from 3Q 2023).Reported Earnings • Aug 30Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: US$1.65m (up 8.8% from 2Q 2023). Net loss: US$1.40m (loss narrowed 40% from 2Q 2023).お知らせ • Aug 01ARCpoint Inc. announced that it has received CAD 1.004175 million in fundingOn July 31, 2024, ARCpoint Inc. closed the transaction. The company issued 13,389,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,004,175. In connection with the closing of the offering the company issued 670,900 finder’s shares, 1,013,900 finder’s warrants and paid a cash commission of CAD 60,834 to certain arm’s length finders. Each finder’s warrant entitles the holder thereof to purchase one share at a price of CAD 0.075 per finder’s warrant share until July 31, 2026. The offering remains subject to final acceptance from the TSX Venture Exchange. All securities issued in connection with the offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.お知らせ • Jul 06ARCpoint Inc. announced that it expects to receive CAD 1.5 million in fundingARCpoint Inc. announced a non-brokered private placement to issue up to 20,000,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,500,000 on July 5, 2024. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange.Reported Earnings • Apr 30Full year 2023 earnings releasedFull year 2023 results: Revenue: US$6.67m (down 39% from FY 2022). Net loss: US$8.66m (loss widened 7.7% from FY 2022).Board Change • Mar 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Roger He was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Jan 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$7.2m). Revenue has declined by 60% over the past year. Market cap is less than US$10m (CA$11.0m market cap, or US$8.18m). Minor Risk Shareholders have been diluted in the past year (12% increase in shares outstanding).お知らせ • Jan 23ARCpoint Inc. announced that it has received $1.1 million in fundingOn January 22, 2024, ARCpoint Inc. closed the transaction. The company has now issued 11,000,000 Class A subordinate voting shares at a price of $0.10 per share for the gross proceeds of $1,100,000. Certain insiders of the company purchased or acquired direction or control over a total of 4,000,000 shares as part of the Offering.お知らせ • Jan 04ARCpoint Inc. announced that it expects to receive $1.6 million in fundingARCpoint Inc. announced a non-brokered private placement of up to 16,000,000 subordinated voting common shares at a price of $0.10 per share for the gross proceeds of $1,600,000 on January 2, 2024. The company anticipates that certain directors, officers and insiders of the company will purchase shares in an aggregate amount of up to $450,000 under the offering, The offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.Reported Earnings • Nov 24Third quarter 2023 earnings released: US$0.016 loss per share (vs US$11.81 loss in 3Q 2022)Third quarter 2023 results: US$0.016 loss per share (improved from US$11.81 loss in 3Q 2022). Revenue: US$1.61m (down 5.8% from 3Q 2022). Net loss: US$1.45m (loss narrowed 18% from 3Q 2022).Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.026 loss per share (vs US$6.90 loss in 2Q 2022)Second quarter 2023 results: US$0.026 loss per share. Revenue: US$1.52m (down 33% from 2Q 2022). Net loss: US$2.34m (loss widened 127% from 2Q 2022).お知らせ • Jul 12Arcpoint Inc. Launches MyARCpointLabsARCpoint Inc. reported that it has launched its new consumer e-commerce platform, MyARCpointLabs. MyARCpointLabs was developed to make it easier for both the Company's franchisees to attract and better serve individual healthcare consumers and for consumers to more easily purchase the Company's products and services. ARCpoint's goal is to leverage technology along with brick-and-mortar locations to give consumers access to convenient, cost-effective healthcare information and solutions with transparent, up-front pricing, so that they can be proactive and preventative with their health and well-being. By combining an easy-to-use consumer mobile platform with intuitive digital marketing and scheduling tools, MAPL will help close a growing gap within the healthcare system by delivering preventative healthcare solutions to all those who want them.Reported Earnings • May 20First quarter 2023 earnings released: US$0.023 loss per share (vs US$4.64 profit in 1Q 2022)First quarter 2023 results: US$0.023 loss per share (down from US$4.64 profit in 1Q 2022). Revenue: US$1.71m (down 69% from 1Q 2022). Net loss: US$2.03m (down 393% from profit in 1Q 2022).お知らせ • May 16Arcpoint Inc. Announces Appointment of Mr. Bob Mann as President of Arcpoint FranchiseARCpoint Inc. announced that Mr. Bob Mann has been appointed President of ARCpoint Franchise Group LLC (AFG), a wholly owned US subsidiary of the Company that operates ARCpoints franchise business. Mr. Mann comes to AFG with over 20 years of successful leadership and innovation experience including 15 years in the US diagnostic services space. He will be responsible for driving both top line growth at all franchisee locationsand growing the Companys distribution network from the current 134 locations. Mr. Mann started his diagnostics career at Quest Diagnostics in 2006 as a Sales Manager for Quests NC and SC sales teams before taking on different roles including: leading new business acquisition, developing strategiesfor growth and working with health plans and large healthcare entities. In 2012, he joined Cordant Health Solutions, then known as Sterling Healthcare, which went on to acquire five laboratories and six pharmacies to grow into one of the leading toxicology labs and behavioral health pharmacies in the US. For the past 8 years, Mr. Mann served as part of Cordants Executive Leadership team and held several key roles, including as Executive Vice President of Cordants Integrated Services group and overseeing sales and strategy. He was instrumental in the development of many of Cordants strategic toxicology and pharmacy offerings and also led the development of Cordants novel behavioral health pharmacy program that integrated laboratory and pharmacy services.Reported Earnings • Apr 15Full year 2022 earnings released: US$0.10 loss per share (vs US$38.48 profit in FY 2021)Full year 2022 results: US$0.10 loss per share (down from US$38.48 profit in FY 2021). Revenue: US$10.9m (down 43% from FY 2021). Net loss: US$8.04m (down 240% from profit in FY 2021).Buying Opportunity • Dec 10Now 31% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be CA$0.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only.お知らせ • Nov 16+ 1 more updateARCpoint Inc. to Report Q3, 2022 Results on Nov 28, 2022ARCpoint Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 28, 2022Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Mark Orsmond was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、ARCpoint は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSXV:ARC - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20251-2-1-1N/A9/30/20251-3-1-1N/A6/30/202533-2-2N/A3/31/202542-2-2N/A12/31/202461-3-3N/A9/30/20246-1-3-3N/A6/30/20247-7-3-3N/A3/31/20247-8-5-4N/A12/31/20237-9-5-4N/A9/30/20236-12-5-4N/A6/30/20236-12-6-5N/A3/31/20237-11-4-3N/A12/31/202211-8-20N/A9/30/202215-111N/A6/30/202219223N/A3/31/202219445N/A12/31/202119655N/A12/31/202013633N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ARCの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ARCの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ARCの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ARCの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ARCの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ARCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 16:46終値2026/06/05 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ARCpoint Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • 3hARCpoint Inc. Announces CEO ChangesARCpoint Inc. announced that its Board of Directors had appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. Mr. Kendall’s appointment remains subject to acceptance by the TSX Venture Exchange, including acceptance of the Exchange’s required Personal Information Form and completion of customary Exchange review and verification procedures. In connection with Mr. Kendall’s appointment, John Constantine has stepped down as Chief Executive Officer of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. Peter Kendall has more than twenty years of healthcare commercialization experience. His prior roles include President and Chief Commercialization Officer of AI/ML Innovations Inc., Chief Executive Officer of Yurek Pharmacy Group, and National Director at Medisys Health Group, subsequently acquired by TELUS Health. Mr. Kendall’s initial engagement is for a term of 90 days. During this period, Mr. Kendall will work with the Board and management to assess the Company's business model, MAPL technology platform, commercial relationships, assets and strategic direction, and to provide recommendations to the Board on the best commercial and financial path forward for the Company and its stakeholders.
お知らせ • 22hArcpoint Inc. Announces Step Down of John Constantine as PresidentARCpoint Inc. announced that John Constantine has stepped down as President of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. The Company’s Board members remain Zelong “Roger” He, David Keys, John Constantine and Adam Ho.
Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Roger He was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 30Arcpoint Inc. Announces Felix Mirando Resignation of Board MemberARCpoint Inc. reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective April 28, 2026.
Reported Earnings • Mar 05Full year 2025 earnings released: US$0.017 loss per share (vs US$0.013 profit in FY 2024)Full year 2025 results: US$0.017 loss per share (down from US$0.013 profit in FY 2024). Revenue: US$605.7k (down 89% from FY 2024). Net loss: US$2.12m (down 256% from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.3m free cash flow). Share price has been highly volatile over the past 3 months (39% average weekly change). Negative equity (-US$7.5m). Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (CA$1.28m market cap, or US$918.6k). Minor Risk Revenue is less than US$5m (US$1.5m revenue).
Reported Earnings • Nov 30Third quarter 2025 earnings released: US$0.004 loss per share (vs US$0.051 profit in 3Q 2024)Third quarter 2025 results: US$0.004 loss per share (down from US$0.051 profit in 3Q 2024). Revenue: US$113.7k (down 91% from 3Q 2024). Net loss: US$507.2k (down 110% from profit in 3Q 2024).
Reported Earnings • Aug 27Second quarter 2025 earnings released: US$0.006 loss per share (vs US$0.015 loss in 2Q 2024)Second quarter 2025 results: US$0.006 loss per share (improved from US$0.015 loss in 2Q 2024). Net loss: US$704.2k (loss narrowed 50% from 2Q 2024).
お知らせ • Jul 02ARCpoint Inc., Annual General Meeting, Aug 25, 2025ARCpoint Inc., Annual General Meeting, Aug 25, 2025.
Reported Earnings • May 28First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: US$177.4k (down 89% from 1Q 2024). Net loss: US$633.5k (loss narrowed 57% from 1Q 2024).
New Risk • May 08New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Negative equity (-US$6.6m). Market cap is less than US$10m (CA$11.6m market cap, or US$8.37m). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (26% increase in shares outstanding).
お知らせ • Mar 09ARCpoint Inc. announced that it has received CAD 0.8 million in fundingOn March 7, 2025, ARCpoint Inc., closed the transaction. As a part of the transaction, the company paid CAD 36,057.60 as cash commission, issued 428,400 finder’s shares, 536,400 finder’s warrants. The transaction included participation from Felix Mirando and Adam Ho, purchased or acquired direction or control over a total of 764,199 units as part of the offering.
お知らせ • Jan 31ARCpoint Inc. announced that it expects to receive CAD 0.8 million in fundingARCpoint Inc. announced a non-brokered private placement to issue 10,000,000 units at issue price of CAD 0.08 per unit for gross proceeds of CAD 800,000 on January 31, 2025. Each Unit will be comprised of one Class A Subordinate Voting Share of the Company and one warrant to purchase an additional Share at CAD 0.12 for 24 months from closing. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Subject to compliance with applicable securities laws and the approval of the TSX Venture Exchange, finders’ fees may be payable to eligible arm’s length persons with respect to certain subscriptions accepted by the Company.
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (50% average weekly change). Negative equity (-US$6.1m). Earnings have declined by 65% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (CA$9.43m market cap, or US$6.58m).
お知らせ • Dec 31An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million.An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million on December 30, 2024. A cash consideration of $0.48 million will be paid by the buyer.
Reported Earnings • Nov 29Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.016 loss in 3Q 2023)Third quarter 2024 results: EPS: US$0.051 (up from US$0.016 loss in 3Q 2023). Revenue: US$1.22m (down 24% from 3Q 2023). Net income: US$5.19m (up US$6.64m from 3Q 2023).
Reported Earnings • Aug 30Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: US$1.65m (up 8.8% from 2Q 2023). Net loss: US$1.40m (loss narrowed 40% from 2Q 2023).
お知らせ • Aug 01ARCpoint Inc. announced that it has received CAD 1.004175 million in fundingOn July 31, 2024, ARCpoint Inc. closed the transaction. The company issued 13,389,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,004,175. In connection with the closing of the offering the company issued 670,900 finder’s shares, 1,013,900 finder’s warrants and paid a cash commission of CAD 60,834 to certain arm’s length finders. Each finder’s warrant entitles the holder thereof to purchase one share at a price of CAD 0.075 per finder’s warrant share until July 31, 2026. The offering remains subject to final acceptance from the TSX Venture Exchange. All securities issued in connection with the offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.
お知らせ • Jul 06ARCpoint Inc. announced that it expects to receive CAD 1.5 million in fundingARCpoint Inc. announced a non-brokered private placement to issue up to 20,000,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,500,000 on July 5, 2024. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange.
Reported Earnings • Apr 30Full year 2023 earnings releasedFull year 2023 results: Revenue: US$6.67m (down 39% from FY 2022). Net loss: US$8.66m (loss widened 7.7% from FY 2022).
Board Change • Mar 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Roger He was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Jan 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$7.2m). Revenue has declined by 60% over the past year. Market cap is less than US$10m (CA$11.0m market cap, or US$8.18m). Minor Risk Shareholders have been diluted in the past year (12% increase in shares outstanding).
お知らせ • Jan 23ARCpoint Inc. announced that it has received $1.1 million in fundingOn January 22, 2024, ARCpoint Inc. closed the transaction. The company has now issued 11,000,000 Class A subordinate voting shares at a price of $0.10 per share for the gross proceeds of $1,100,000. Certain insiders of the company purchased or acquired direction or control over a total of 4,000,000 shares as part of the Offering.
お知らせ • Jan 04ARCpoint Inc. announced that it expects to receive $1.6 million in fundingARCpoint Inc. announced a non-brokered private placement of up to 16,000,000 subordinated voting common shares at a price of $0.10 per share for the gross proceeds of $1,600,000 on January 2, 2024. The company anticipates that certain directors, officers and insiders of the company will purchase shares in an aggregate amount of up to $450,000 under the offering, The offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.
Reported Earnings • Nov 24Third quarter 2023 earnings released: US$0.016 loss per share (vs US$11.81 loss in 3Q 2022)Third quarter 2023 results: US$0.016 loss per share (improved from US$11.81 loss in 3Q 2022). Revenue: US$1.61m (down 5.8% from 3Q 2022). Net loss: US$1.45m (loss narrowed 18% from 3Q 2022).
Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.026 loss per share (vs US$6.90 loss in 2Q 2022)Second quarter 2023 results: US$0.026 loss per share. Revenue: US$1.52m (down 33% from 2Q 2022). Net loss: US$2.34m (loss widened 127% from 2Q 2022).
お知らせ • Jul 12Arcpoint Inc. Launches MyARCpointLabsARCpoint Inc. reported that it has launched its new consumer e-commerce platform, MyARCpointLabs. MyARCpointLabs was developed to make it easier for both the Company's franchisees to attract and better serve individual healthcare consumers and for consumers to more easily purchase the Company's products and services. ARCpoint's goal is to leverage technology along with brick-and-mortar locations to give consumers access to convenient, cost-effective healthcare information and solutions with transparent, up-front pricing, so that they can be proactive and preventative with their health and well-being. By combining an easy-to-use consumer mobile platform with intuitive digital marketing and scheduling tools, MAPL will help close a growing gap within the healthcare system by delivering preventative healthcare solutions to all those who want them.
Reported Earnings • May 20First quarter 2023 earnings released: US$0.023 loss per share (vs US$4.64 profit in 1Q 2022)First quarter 2023 results: US$0.023 loss per share (down from US$4.64 profit in 1Q 2022). Revenue: US$1.71m (down 69% from 1Q 2022). Net loss: US$2.03m (down 393% from profit in 1Q 2022).
お知らせ • May 16Arcpoint Inc. Announces Appointment of Mr. Bob Mann as President of Arcpoint FranchiseARCpoint Inc. announced that Mr. Bob Mann has been appointed President of ARCpoint Franchise Group LLC (AFG), a wholly owned US subsidiary of the Company that operates ARCpoints franchise business. Mr. Mann comes to AFG with over 20 years of successful leadership and innovation experience including 15 years in the US diagnostic services space. He will be responsible for driving both top line growth at all franchisee locationsand growing the Companys distribution network from the current 134 locations. Mr. Mann started his diagnostics career at Quest Diagnostics in 2006 as a Sales Manager for Quests NC and SC sales teams before taking on different roles including: leading new business acquisition, developing strategiesfor growth and working with health plans and large healthcare entities. In 2012, he joined Cordant Health Solutions, then known as Sterling Healthcare, which went on to acquire five laboratories and six pharmacies to grow into one of the leading toxicology labs and behavioral health pharmacies in the US. For the past 8 years, Mr. Mann served as part of Cordants Executive Leadership team and held several key roles, including as Executive Vice President of Cordants Integrated Services group and overseeing sales and strategy. He was instrumental in the development of many of Cordants strategic toxicology and pharmacy offerings and also led the development of Cordants novel behavioral health pharmacy program that integrated laboratory and pharmacy services.
Reported Earnings • Apr 15Full year 2022 earnings released: US$0.10 loss per share (vs US$38.48 profit in FY 2021)Full year 2022 results: US$0.10 loss per share (down from US$38.48 profit in FY 2021). Revenue: US$10.9m (down 43% from FY 2021). Net loss: US$8.04m (down 240% from profit in FY 2021).
Buying Opportunity • Dec 10Now 31% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be CA$0.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
お知らせ • Nov 16+ 1 more updateARCpoint Inc. to Report Q3, 2022 Results on Nov 28, 2022ARCpoint Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 28, 2022
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Mark Orsmond was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.